The drugs Ozempic and Wegovy have been quite impactful in the obesity treatment scene, being considered some of the best selling drugs of all time. However, like any medicine, they are not without side effects and specific requirements.
The pharmaceutical industry is looking to develop the next generation of obesity drugs in pill form. This approach aims to overcome the challenges associated with administering medication through injections and provide a more convenient option for patients.
see more
Alert: THIS poisonous plant landed a young man in the hospital
Google develops AI tool to help journalists in…
Easy-to-swallow pills for the trade have the potential to attract an even larger market and be more profitable when compared to injectable formulations.
The convenience and simplicity of using a pill are clear advantages, especially for those who prefer to avoid injections or have difficulties with administering medication in this way.
Seeking this new proposal, pharmaceutical companies Novo Nordisk, Eli Lilly and Pfizer are currently competing to become the first to introduce a highly effective, safe and effective weight loss pill. profitable.
Pharmaceutical industry prepares slimming pill
Three giants of the pharmaceutical industry - Novo Nordisk, Eli Lilly and Pfizer - are developing plans to market tablet versions of injectable weight-loss drugs.
Among them, Novo Nordisk appears to be leading with its oral semaglutide product, which shares the same key ingredient as weekly injections of Ozempic and Wegovy.
Novo Nordisk's daily pill is similar to its type 2 diabetes drug, Rybelsus, which contains a low dose of semaglutide. This approach aims to provide patients with a more convenient, easier-to-take option to help with weight management.
Recently, Pfizer scrapped one of its obesity drug candidates due to safety concerns. During a clinical trial of the pills, patients given the drug had elevated levels of liver enzymes, which could indicate possible liver damage.
The timeline for the release of the pill versions of Wegovy and Ozempic is still unclear, but Novo Nordisk appears to be leading the way in this development. The Danish company recently announced its intention to seek FDA and EU approval later in 2023.
Semaglutide, the main ingredient of these drugs, has been available in pill form since 2020 in USA under the brand name Rybelsus, but currently approved doses are too low to promote weight loss significant.
Lover of movies and series and everything that involves cinema. An active curious on the networks, always connected to information about the web.